• Citer

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

par Stopeck, Alison T;Lipton, Allan;Body, Jean-Jacques ;Steger, Guenther G;Tonkin, Katia;de Boer, Richard H;Lichinitser, Mikhail;Fujiwara, Yasuhiro;Yardley, Denise A;Viniegra, María;Fan, Michelle;Jiang, Qi;Dansey, Roger;Jun, Susie;Braun, Ada
Référence Journal of clinical oncology, 28, 35, page (5132-5139)
Publication Publié, 2010-12

Article révisé par les pairs

• Détails
• Contenu

Résumé :

This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases.